A Phase 3 Randomized, Double-blind, Placebo-controlled Study to
Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal
Antibody With an Extended Half-life Against Respiratory Syncytial
Virus, in Healthy Late Preterm and Term Infants (MELODY)
Please contact us for more information or to learn if you are eligible to participate.
